Surgical resection remains the basis for definitive treatment of thyroid-stimulating hormone (TSH)-secreting pituitary adenomas.1-3 These rare tumors comprise 1 to 2.8% of all pituitary adenomas and are typically invasive neoplasms.3,4 The combination of surgery and radiotherapy has achieved short-term cures in approximately 41 to 46% of patients, but these reports included follow-up from only 3 to 36 months.3'5 Information on the current management of TSH-secreting pituitary adenomas is scarce in the neurosurgical literature. However, a review of all literature revealed that long-acting somatostatin analogues have proven to be an effective adjunct therapy for TSH-secreting pituitary adenomas. Octreotide has been shown to reduce TSH secretion in almost all cases, normalize thyroid hormone levels in three-fourths of cases, and shrink tumors in up to one-,third of patients receiving long-term treatment. 1, 6, 7 This review includes a report of a unique case of a TSH-secreting pituitary adenoma to illustrate the dramatic effect of pretreatment with octreotide therapy on clinical symptomatology, TSH levels, thyroid hormone levels, and tumor volume. While a combination of octreotide pretreatment followed by surgical resection led to clinical remission in our patient, it remains to be de-89 Skull
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CASE REPORT
A 52-year-old white male with a 7-year history of scleroderma was referred for evaluation and management of hypogonadotropic hypogonadism The patient complained of hot flashes, hair loss, and decreased libido and erectile function. In addition, he had lost 28 pounds over the preceding 18 months. He denied headache or visual disturbance. On physical examination, he had a diffusely enlarged thyroid gland, but no signs of ophthalmopathy or dermopathy. In October 1995, a repeat MRI failed to demonstrate further shrinkage of the adenoma. Because of the lack of further decrease in tumor size, the cost and inconvenience of thrice daily injections, and the belief that surgical resection might decrease or obviate continued therapy, transsphenoidal resection was elected.
In December 1995, gross resection of the pituitary adenoma was undertaken. During the operation the yellow-tan adenoma was found to be slightly tougher than usual but of average vascularity without signs of hemorrhage. After exploration, the diaphragma sellae, the medial walls of the cavernous sinuses, and the floor of the sella were clear of tumor and the diaphragma sellae had descended well into the sella.
Immunoperoxidase stains revealed strong reactivity with TSH and chromogranin antisera, weak reactivity to follicle-stimulating hormone (FSH), and no reactivity with anti-luteinizing hormone. A biopsy of the anterior sellar dura proved positive for microinvasion. The patho- Repeat MRI in February 1996 revealed a significant decrease in size of the tumor (Fig. 3) . Enhancing tissue extending up to and possibly into the cavernous sinus was still apparent. Nine months after surgery and discontinuation of octreotide and antithyroid medications, the patient remained clinically euthyroid (TSH 0.56 ,IU/mL, free thyroxine index 4.9 ig/dL, and T3 99 ng/dL).
DISCUSSION
Since the advent of TSH monoclonal antibodies in the mid-1980s and immunometric assays, the diagnosis tides is found and synthesized in the central nervous system, peripheral nervous system, pancreatic islet D-cells, and the epithelial glandular and neuronal cells of the gastrointestinal tract. They can act as neurotransmitters, local hormones, systemic hormones, autocrine agents, or paracrine agents that inhibit the secretion of other hormones or cell products.'1 Somatostatin acts to inhibit the tonic and phasic secretion of growth hormone and thyrotropin by the anterior pituitary. Several mechanisms of action have been postulated for the inhibition of TSH, involving cAMP levels, intracellular Ca+2 concentrations, and somatostatin binding sites coupled to inhibitory G-proteins.5 Somatostatin has been shown to inhibit adenylate cyclase and reduce cAMP levels in direct relation to the amount of somatostatin binding sites. Other mechanisms independent of cAMP levels relate to somatostatin-induced membrane hyperpolarization causing decreased intracellular Ca+2 in the thyrotrope cells which in turn reduces TSH secretion. 12 Because of a short serum half-life of approximately 2 minutes, somatostatin was not used therapeutically until the development of the long-acting somatostatin analogue octreotide. The elimination half-life of octreotide is 1.5 hours and duration of action is up to 12 hours. Subsequently, octreotide has been shown to be effective in controlling hypersecretion of thyrotropin and the associated hyperthyroidism due to TSH-secreting pituitary adenomas. ' Our patient is the 13th reported case of documented tumor shrinkage after octreotide therapy. Of these 13 patients, 9 demonstrated a 30 to 70% reduction in tumor volume and 4 patients had minor or unspecified tumor shrinkage. The average dose of octreotide was 100 ,ug administered subcutaneously every 8 hours. The course of treatment before tumor shrinkage was noted ranged from 2 weeks to 18 months. Information on 5 of the 13 patients regarding subsequent surgical management revealed that 4 patients underwent gross resection and 1 patient underwent subtotal surgical debulking after pretreatment with octreotide. Half of the patients with gross removal were cured and the other half had clinical relapse of their hyperthyroidism. Unfortunately, follow-up was not reported beyond 3 years. These reports of case series represent retrospective, uncontrolled reviews with relatively short follow-up and therefore conclusions regarding the ultimate impact of pretreatment of these tumors with octreotide and the optimal management of these patients must remain the bias of the treating physician.
Our patient's course illustrates the beneficial effect of octreotide on disease symptoms, thyroid hormone levels, and tumor volume, possibly facilitating surgical removal and clinical remission. The duration of remission has yet to be seen and radiation therapy may have to be considered in the future. This combination therapy, however, represents a useful management paradigm for treatment of patients with these rare tumors.
